Novel dosage form

A solid oral pharmaceutical dosage form according to any of the previous claims, wherein there are one or more additional layers between the layers or on top of the third layer.

A solid oral pharmaceutical dosage form according to any of the previous claims, wherein the first delayed-release layer comprises an enteric polymer selected from the group comprising esters of cellulose and its derivatives (cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, hydroxypropyl methylcellulose acetate succinate), polyvinyl acetate phthalate, pH-sensitive methacrylic acid copolymers and shellac.

A solid oral pharmaceutical dosage form according to any of the previous claims, wherein the second sustained-release layer comprises one or more pH-independent pharmaceutically acceptable excipients.

A solid oral pharmaceutical dosage form according to any of the preceding claims, wherein the retard polymer is selected from the group comprising cellulose derivatives, sodium carboxymethylcellulose, hydoxyalkylcelluloses such as hydroxypropylmethylcellulose and hydroxypropylcellulose, polyethylene oxide, alkylcelluloses such as methylcellulose and ethylcellulose, polyethylene glycol, cellulose acetate, cellulose acetate butyrate, ammonio methacrylate copolymer, polyacrylate dispersion, polyvinylpyrrolidone polyvinyl acetate and mixture thereof.

A solid oral pharmaceutical dosage form according to any of the preceding claims, wherein each individual layer may further comprise of excipients like binder, lubricant, plasticizer, pore builder, solvent, or a buffer solution for pH adjustment.

A solid oral pharmaceutical dosage form according to any of the preceding claims, wherein bi-modal release profile means an immediate release of 30-50% of the active pharmaceutical ingredient, and a second delayed release of the remaining 70-50% of the active pharmaceutical ingredient.

A solid oral pharmaceutical dosage form according to any of the preceding claims, wherein the dosage form is administered once per day.

A solid oral pharmaceutical dosage form according to any of the preceding claims, additionally comprising compounds for abuse prevention.

A solid oral pharmaceutical dosage form according to any of the preceding claims for use in the treatment of a disease or modality selected from the group comprising Attention Deficit Hyperactivity Disorder (ADHD), diabetes, pain, insomnia, high blood pressure, allergies such as allergic rhinitis, and gastroesophageal reflux diseases.

A solid oral pharmaceutical dosage form according to any of the previous claims, wherein the at least one active pharmaceutical ingredient is methylphenidate or a pharmaceutical acceptable salt thereof, wherein the methylphenidate is a racemic mixture of d- and l-threo enantiomers or the d-threo enantiomer of methylphenidate or a pharmaceutical salt thereof.

A solid oral pharmaceutical dosage form according to any of the preceding claims, wherein the dosage form comprises 5-100 mg methylphenidate or the hydrochloride salt thereof.